Atypical antipsychotic-induced weight gain: insights into mechanisms of action
- PMID: 22133326
- DOI: 10.2165/11596300-000000000-00000
Atypical antipsychotic-induced weight gain: insights into mechanisms of action
Abstract
Prescriptions for second-generation antipsychotics (SGAs) have surpassed those for first-generation agents in the treatment of schizophrenia and bipolar disorder. While SGAs have the benefit of a much reduced risk of causing movement disorders, they have been associated with weight gain and metabolic effects. These adverse reactions are not uncommon, and threaten to have a significant impact on the patient's health over the long-term treatment that the patient requires. Currently, the aetiology of these effects is not known. This article reviews the data exploring the weight gain phenomenon. The literature was reviewed from searches of PubMed and the references of major articles in the field. The SGAs present a heterogeneous risk for weight gain. In addition, different individuals receiving the same drug can exhibit substantially different weight changes. This pattern suggests that a group of factors are associated with the weight gain phenomenon rather than a single mechanism. Coupled with the genetic profile that the patient brings to the treatment, the risk for SGA-induced weight gain will be different for different drugs and different individuals. Targets for exploration of the weight gain phenomenon include receptor interactions involving serotonin, histamine, dopamine, adrenergic, cannabinoid and muscarinic receptors. The association of SGA-induced weight gain and the role of orexigenic and anorexigenic peptides are reviewed. Also, a brief discussion of genetic factors associated with SGA-induced weight gain is presented, including that of the serotonin 5-HT(2C) receptor gene (HTR2C) and the cannabinoid 1 receptor gene (CNR1). The most promising data associated with SGA-induced weight gain include investigations of the histamine H(1), 5-HT(2A), 5-HT(2C), muscarinic M(3) and adrenergic receptors. In addition, work in the genetic area promises to result in a better understanding of the variation in risk associated with different individuals.
Similar articles
-
H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.Neuropsychopharmacology. 2003 Mar;28(3):519-26. doi: 10.1038/sj.npp.1300027. Neuropsychopharmacology. 2003. PMID: 12629531
-
Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle.J Clin Psychiatry. 2001;62 Suppl 23:45-66. J Clin Psychiatry. 2001. PMID: 11603885 Review.
-
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.J Clin Psychiatry. 2012 Aug;73(8):1077-86. doi: 10.4088/JCP.11m06916. J Clin Psychiatry. 2012. PMID: 22967772 Clinical Trial.
-
Multiple genetic factors in olanzapine-induced weight gain in schizophrenia patients: a cohort study.J Clin Psychiatry. 2008 Sep;69(9):1416-22. doi: 10.4088/jcp.v69n0909. J Clin Psychiatry. 2008. PMID: 19193342
-
Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder.Clin Drug Investig. 2011;31(7):455-82. doi: 10.2165/11589060-000000000-00000. Clin Drug Investig. 2011. PMID: 21495734 Review.
Cited by
-
A propensity score matching analysis for cardio metabolic risk of antipsychotics in patients with schizophrenia using Japanese claims data.BMC Psychiatry. 2020 Dec 9;20(1):584. doi: 10.1186/s12888-020-02987-1. BMC Psychiatry. 2020. PMID: 33298025 Free PMC article.
-
A phenotypic Caenorhabditis elegans screen identifies a selective suppressor of antipsychotic-induced hyperphagia.Nat Commun. 2018 Dec 10;9(1):5272. doi: 10.1038/s41467-018-07684-y. Nat Commun. 2018. PMID: 30532051 Free PMC article.
-
Resting Energy Expenditure and Body Composition in Children and Adolescents With Genetic, Hypothalamic, Medication-Induced or Multifactorial Severe Obesity.Front Endocrinol (Lausanne). 2022 Jul 11;13:862817. doi: 10.3389/fendo.2022.862817. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 35898454 Free PMC article.
-
Genetic Polymorphisms Associated With the Pharmacokinetics, Pharmacodynamics and Adverse Effects of Olanzapine, Aripiprazole and Risperidone.Front Pharmacol. 2021 Jul 14;12:711940. doi: 10.3389/fphar.2021.711940. eCollection 2021. Front Pharmacol. 2021. PMID: 34335273 Free PMC article. Review.
-
Clozapine suppresses NADPH oxidase activation, counteracts cytosolic H2O2, and triggers early onset mitochondrial dysfunction during adipogenesis of human liposarcoma SW872 cells.Redox Biol. 2023 Nov;67:102915. doi: 10.1016/j.redox.2023.102915. Epub 2023 Oct 12. Redox Biol. 2023. PMID: 37866162 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources